Premium
Molecular assessment of vitamin D receptor polymorphism as a valid predictor to the response of interferon/ribavirin‐based therapy in Egyptian patients with chronic hepatitis C
Author(s) -
Abdelsalam Ahmed,
Rashed Laila,
Salman Tarek,
Hammad Lamiaa,
Sabry Dina
Publication year - 2016
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12353
Subject(s) - foki , taqi , calcitriol receptor , ribavirin , medicine , pegylated interferon , gastroenterology , vitamin d and neurology , hepatitis c virus , restriction fragment length polymorphism , immunology , genotype , polymorphism (computer science) , virus , biology , gene , genetics
Objective The aim of this study was to find an association between serum concentration of vitamin D and vitamin D receptor ( VDR ) polymorphisms to achieve a sustained virological response (SVR). Methods We conducted a case‐control study in which 250 participants were recruited and divided into three groups (100 chronic hepatitis C [CHC] patients who achieved SVR, 100 CHC patients who did not achieve SVR and 50 apparently healthy individuals as controls). Blood samples were collected to measure serum vitamin D concentration, and four VDR polymorphisms ( FokI, ApaI, TaqI, and BsmI ) were detected using polymerase chain reaction‐restriction fragment length polymorphism. Results Non‐responders were found to have significantly low vitamin D concentration compared with responders and control groups. Concerning VDR polymorphisms, both FokI and TaqI polymorphisms were associated with successful treatment. Conclusion Vitamin D concentration, FokI , and TaqI may be considered as the predictors for the response of CHC patients to a combination therapy of pegylated interferon and ribavirin.